{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T13:27:24Z","timestamp":1782998844330,"version":"3.54.5"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cllc.2021.05.012","type":"journal-article","created":{"date-parts":[[2021,6,12]],"date-time":"2021-06-12T11:35:08Z","timestamp":1623497708000},"page":"e87-e89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non\u2013Small-Cell Lung Cancer and High PD-L1 Expression"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza E.L.","family":"Hendriks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2021.05.012_bib0001","first-page":"00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non\u2013small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%","author":"Reck","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.cllc.2021.05.012_bib0002","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1016\/j.jtho.2021.01.143","article-title":"KEYNOTE-042 3-year survival update: 1L pembrolizumab vs platinum-based chemotherapy for PD-L1+ locally advanced\/metastatic NSCLC","volume":"16","author":"Cho","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.05.012_bib0003","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50%: randomized, double-blind phase III KEYNOTE-598 study","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.05.012_bib0004","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.05.012_bib0005","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2021.05.012_bib0006","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s00262-020-02613-9","article-title":"Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of \u2265\u200950","volume":"69","author":"Cortellini","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.cllc.2021.05.012_bib0007","unstructured":"Peters S et\u00a0al. Real world effectiveness of PD-(L)1 inhibitors alone or in combination with chemotherapy in first-line PDL1-high non-squamous lung cancer. ESMO Virtual Plenary 8th April 2021. https:\/\/www.esmo.org\/meetings\/ (Assessed April 08, 2021)."},{"key":"10.1016\/j.cllc.2021.05.012_bib0008","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2012small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2021.05.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206370","article-title":"Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States","volume":"13","author":"Velcheti","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2021.05.012_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/jclinpath-2020-206709","article-title":"Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status","volume":"74","author":"Holmes","year":"2021","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cllc.2021.05.012_bib0011","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2019.10.002","article-title":"Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors","volume":"46","author":"Hopkins","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2021.05.012_bib0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000500885","article-title":"Immuno-oncological treatment and tumor mass in non-small cell lung cancer: case-control analysis of overall survival in routine clinical practice","volume":"97","author":"Faehling","year":"2019","journal-title":"Oncology"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:12:04Z","timestamp":1761505924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730421001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1525730421001492"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.05.012","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non\u2013Small-Cell Lung Cancer and High PD-L1 Expression","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}